Kurzfassung

A Phase III, Open-label, Randomised Study of Neoadjuvant
Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed
by Adjuvant Durvalumab With or Without Chemotherapy Versus
Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by
Adjuvant Pembrolizumab With or Without Chemotherapy for the
Treatment of Adult Patients With Previously Untreated
Triple-Negative or Hormone Receptor-low/HER2-negative Breast
Cancer (D926QC00001; TROPION-Breast04)